Jianmin Pharmaceutical Group Co Ltd (600976) — Strategic Asset Allocation Index
Jianmin Pharmaceutical Group Co Ltd (600976) has a Strategic Asset Allocation Index of 21.8% as of June 2023. Strategic assets (PP&E of CN¥430.27 Million plus long-term investments of CN¥-) total CN¥430.27 Million, measured against net assets of CN¥1.98 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Jianmin Pharmaceutical Group Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Jianmin Pharmaceutical Group Co Ltd Strategic Asset Allocation Index (2001–2022)
This chart shows how Jianmin Pharmaceutical Group Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2001 to 2022. As of June 2023, the index stands at 21.8%, representing strategic assets of CN¥430.27 Million against net assets of CN¥1.98 Billion CNY. See Jianmin Pharmaceutical Group Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Jianmin Pharmaceutical Group Co Ltd (2001–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Jianmin Pharmaceutical Group Co Ltd from 2001 to 2022, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 600976 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 22.4% | CN¥417.65 Million | CN¥417.65 Million | CN¥- | CN¥1.87 Billion | ▼ -2.9 pp |
| 2021 | 25.3% | CN¥396.65 Million | CN¥396.65 Million | CN¥- | CN¥1.57 Billion | ▼ -2.8 pp |
| 2020 | 28.1% | CN¥371.76 Million | CN¥371.76 Million | CN¥- | CN¥1.32 Billion | ▲ +0.5 pp |
| 2019 | 27.5% | CN¥332.75 Million | CN¥332.75 Million | CN¥- | CN¥1.21 Billion | ▼ -16.4 pp |
| 2018 | 44.0% | CN¥503.49 Million | CN¥273.29 Million | CN¥230.21 Million | CN¥1.15 Billion | ▲ +4.1 pp |
| 2017 | 39.9% | CN¥441.74 Million | CN¥245.55 Million | CN¥196.20 Million | CN¥1.11 Billion | ▲ +2.6 pp |
| 2016 | 37.3% | CN¥385.06 Million | CN¥239.69 Million | CN¥145.37 Million | CN¥1.03 Billion | ▲ +5.5 pp |
| 2015 | 31.9% | CN¥317.77 Million | CN¥231.26 Million | CN¥86.52 Million | CN¥997.36 Million | ▲ +9.2 pp |
| 2014 | 22.7% | CN¥227.30 Million | CN¥227.30 Million | CN¥- | CN¥1.00 Billion | ▼ -3.5 pp |
| 2013 | 26.2% | CN¥246.28 Million | CN¥246.28 Million | CN¥- | CN¥940.46 Million | ▼ -0.8 pp |
| 2012 | 27.0% | CN¥243.63 Million | CN¥243.63 Million | CN¥- | CN¥903.10 Million | ▼ -1.3 pp |
| 2011 | 28.3% | CN¥248.16 Million | CN¥248.16 Million | CN¥- | CN¥876.97 Million | ▼ -2.1 pp |
| 2010 | 30.4% | CN¥257.62 Million | CN¥257.62 Million | CN¥- | CN¥848.81 Million | ▼ -6.1 pp |
| 2009 | 36.5% | CN¥299.31 Million | CN¥299.31 Million | CN¥- | CN¥820.32 Million | ▲ +1.1 pp |
| 2008 | 35.4% | CN¥269.71 Million | CN¥269.71 Million | CN¥- | CN¥761.24 Million | ▲ +0.9 pp |
| 2007 | 34.5% | CN¥256.19 Million | CN¥256.19 Million | CN¥- | CN¥742.63 Million | ▼ -6.0 pp |
| 2006 | 40.5% | CN¥310.60 Million | CN¥310.60 Million | CN¥- | CN¥766.61 Million | ▼ -2.6 pp |
| 2005 | 43.2% | CN¥327.88 Million | CN¥327.88 Million | CN¥- | CN¥759.65 Million | ▲ +1.0 pp |
| 2004 | 42.2% | CN¥297.60 Million | CN¥297.60 Million | CN¥- | CN¥705.12 Million | ▼ -38.9 pp |
| 2003 | 81.1% | CN¥235.38 Million | CN¥235.38 Million | CN¥- | CN¥290.32 Million | ▲ +21.4 pp |
| 2002 | 59.6% | CN¥155.38 Million | CN¥155.38 Million | CN¥- | CN¥260.54 Million | ▲ +8.6 pp |
| 2001 | 51.0% | CN¥119.21 Million | CN¥119.21 Million | CN¥- | CN¥233.57 Million | — |